{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:45:29Z","timestamp":1790837129303,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2327-x","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Response-related predictors of survival in CML"],"prefix":"10.1007","volume":"94","author":[{"given":"Benjamin","family":"Hanfstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"11","key":"2327_CR1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11):710\u2013719","journal-title":"J Clin Oncol"},{"issue":"9584","key":"2327_CR2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370(9584):342\u2013350","journal-title":"Lancet"},{"issue":"35","key":"2327_CR3","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041\u20136051","journal-title":"J Clin Oncol"},{"issue":"22","key":"2327_CR4","first-page":"1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (2009) International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Ann Meet Abstr 114(22):1126","journal-title":"ASH Ann Meet Abstr"},{"issue":"4","key":"2327_CR5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"11","key":"2327_CR6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850\u2013858","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2327_CR7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692","journal-title":"Blood"},{"issue":"26","key":"2327_CR8","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, M\u00fcller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118(26):6760\u20136768","journal-title":"Blood"},{"issue":"24","key":"2327_CR9","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","volume":"117","author":"CM Lucas","year":"2011","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117(24):6660\u20136668","journal-title":"Blood"},{"issue":"2","key":"2327_CR10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","volume":"26","author":"D Marin","year":"2012","unstructured":"Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O\u2019Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K (2012) KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 26(2):296\u2013302","journal-title":"Leukemia"},{"issue":"4","key":"2327_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","volume":"18","author":"KP Ng","year":"2012","unstructured":"Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nothen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18(4):521\u2013528","journal-title":"Nat Med"},{"key":"2327_CR12","doi-asserted-by":"crossref","unstructured":"Mahon FX, Faberes C Fau - Pueyo S, Pueyo S Fau - Cony-Makhoul P, Cony-Makhoul P Fau - Salmi R, Salmi R Fau - Boiron JM, Boiron Jm Fau - Marit G, Marit G Fau - Bilhou-Nabera C, Bilhou-Nabera C Fau - Carrere A, Carrere A Fau - Montastruc M, Montastruc M Fau - Pigneux A, Pigneux A Fau - Bernard P, Bernard P Fau - Reiffers J, Reiffers J Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92(11):4059\u201365","DOI":"10.1182\/blood.V92.11.4059"},{"issue":"9","key":"2327_CR13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","volume":"16","author":"K Merx","year":"2002","unstructured":"Merx K, Muller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16(9):1579\u20131583","journal-title":"Leukemia"},{"issue":"6","key":"2327_CR14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang L, Pearson K, Ferguson JE, Clark RE (2003) The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120(6):990\u2013999","journal-title":"Br J Haematol"},{"issue":"1","key":"2327_CR15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28\u201337","journal-title":"Blood"},{"issue":"6","key":"2327_CR16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"10","key":"2327_CR17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12(10):1181\u20131184","journal-title":"Nat Med"},{"issue":"12","key":"2327_CR18","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hanel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S (2011) Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634\u20131642","journal-title":"J Clin Oncol"},{"issue":"12","key":"2327_CR19","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112(12):4437\u20134444","journal-title":"Blood"},{"issue":"17","key":"2327_CR20","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Shan J, Quintas-Cardama A, Faderl S, Garcia-Manero G, Ravandi F, Rios MB, Cortes J (2011) The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 118(17):4541\u20134546","journal-title":"Blood"},{"issue":"8","key":"2327_CR21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","volume":"87","author":"L Ohm","year":"2012","unstructured":"Ohm L, Arvidsson I, Barbany G, Hast R, Stenke L (2012) Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. Am J Hematol 87(8):760\u2013765","journal-title":"Am J Hematol"},{"issue":"9","key":"2327_CR22","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096\u20132102","journal-title":"Leukemia"},{"issue":"3","key":"2327_CR23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L (2012) Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232\u2013238","journal-title":"J Clin Oncol"},{"issue":"19","key":"2327_CR24","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121(19):3818\u20133824","journal-title":"Blood"},{"issue":"9","key":"2327_CR25","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 26(9):2096\u20132102","journal-title":"Leukemia"},{"key":"2327_CR26","doi-asserted-by":"crossref","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124(4):511\u20138","DOI":"10.1182\/blood-2014-03-566323"},{"issue":"16","key":"2327_CR27","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","volume":"115","author":"Y Alvarado","year":"2009","unstructured":"Alvarado Y, Kantarjian H, O\u2019Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709\u20133718","journal-title":"Cancer"},{"issue":"1","key":"2327_CR28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12185-012-1093-y","volume":"96","author":"D Kim","year":"2012","unstructured":"Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, Kim DW (2012) Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol 96(1):47\u201357","journal-title":"Int J Hematol"},{"issue":"19","key":"2327_CR29","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, Investigators I (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758\u20133765","journal-title":"Blood"},{"issue":"10","key":"2327_CR30","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","volume":"12","author":"I Iacobucci","year":"2006","unstructured":"Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G (2006) Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12(10):3037\u20133042","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2327_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saussele S, Hochhaus A (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32(5):415\u2013423","journal-title":"J Clin Oncol"},{"issue":"11","key":"2327_CR32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","volume":"140","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saussele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Muller MC (2014) Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 140(11):1965\u20131969","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"2327_CR33","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259","journal-title":"N Engl J Med"},{"issue":"24","key":"2327_CR34","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260\u20132270","journal-title":"N Engl J Med"},{"issue":"21","key":"2327_CR35","first-page":"360","volume":"116","author":"B Hanfstein","year":"2010","unstructured":"Hanfstein B, Muller MC, Erben P, Schnittger S, Saussele S, Leitner A, Proetel U, Ehninger G, Hossfeld DK, Kolb H-J, Krause SW, Nerl C, Pralle H, Heim D, Baerlocher GM, Heimpel H, Hehlmann R, Hochhaus A, The German CML-Study Group (2010) Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic myeloid leukemia\u2014a follow-up analysis of the German CML Study IV. ASH Ann Meet Abstr 116(21):360","journal-title":"ASH Ann Meet Abstr"},{"issue":"12","key":"2327_CR36","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17(12):2401\u20132409","journal-title":"Leukemia"},{"issue":"14","key":"2327_CR37","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O\u2019Brien S, Clark R, Goldman J, Marin D (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739\u20132742","journal-title":"Blood"},{"issue":"6","key":"2327_CR38","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","volume":"89","author":"DD Kim","year":"2014","unstructured":"Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH (2014) BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol 89(6):626\u2013632","journal-title":"Am J Hematol"},{"issue":"35","key":"2327_CR39","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Muller MC (2012) Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 30(35):4323\u20134329","journal-title":"J Clin Oncol"},{"issue":"5","key":"2327_CR40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12187","volume":"160","author":"DD Kim","year":"2013","unstructured":"Kim DD, Lee H, Kamel-Reid S, Lipton JH (2013) BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 160(5):630\u2013639","journal-title":"Br J Haematol"},{"issue":"3","key":"2327_CR41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clml.2012.12.005","volume":"13","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, Kantarjian H, Ghanem H, O\u2019Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J (2013) The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 13(3):302\u2013306","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2327_CR42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-2407-13-173","volume":"13","author":"AM Stein","year":"2013","unstructured":"Stein AM, Martinelli G, Hughes TP, Muller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP (2013) Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer 13:173","journal-title":"BMC Cancer"},{"issue":"15","key":"2327_CR43","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brummendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123(15):2317\u20132324","journal-title":"Blood"},{"issue":"11","key":"2327_CR44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029\u20131035","journal-title":"Lancet Oncol"},{"issue":"2","key":"2327_CR45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O\u2019Brien S (2012) Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120(2):291\u2013294","journal-title":"Blood"},{"issue":"24","key":"2327_CR46","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O\u2019Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J (2013) Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121(24):4867\u20134874","journal-title":"Blood"},{"issue":"9","key":"2327_CR47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A (2014) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123(9):1353\u20131360","journal-title":"Blood"},{"issue":"4","key":"2327_CR48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boque C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494\u2013500","journal-title":"Blood"},{"issue":"1","key":"2327_CR49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Brummendorf","year":"2014","unstructured":"Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C (2014) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168(1):69\u201381","journal-title":"Br J Haematol"},{"issue":"3","key":"2327_CR50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","volume":"24","author":"I Iacobucci","year":"2006","unstructured":"Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G (2006) Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 24(3):454\u2013459","journal-title":"J Clin Oncol"},{"issue":"7","key":"2327_CR51","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120(7):2254\u20132264","journal-title":"J Clin Invest"},{"issue":"10","key":"2327_CR52","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.2011.41.1090","volume":"30","author":"DL White","year":"2012","unstructured":"White DL, Hughes TP (2012) Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol 30(10):1144\u20131145","journal-title":"J Clin Oncol"},{"issue":"14","key":"2327_CR53","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"11","key":"2327_CR54","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","volume":"12","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2014) Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 12(11):1590\u20131610","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2327-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2327-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2327-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:24:02Z","timestamp":1598851442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2327-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":54,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2327"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2327-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}